Guard Therapeutics International AB (publ) (STO:GUARD)
Sweden · Delayed Price · Currency is SEK | Market Cap | 27.27M -90.0% |
| Revenue (ttm) | n/a |
| Net Income | -80.99M |
| EPS | n/a |
| Shares Out | 20.17M |
| PE Ratio | n/a |
| Forward PE | 0.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,747 |
| Average Volume | 59,105 |
| Open | 1.346 |
| Previous Close | 1.352 |
| Day's Range | 1.206 - 1.350 |
| 52-Week Range | 0.881 - 27.000 |
| Beta | -0.23 |
| RSI | 56.35 |
| Earnings Date | May 22, 2026 |
About STO:GUARD
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. The company’s pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to treat Sepsis. It also develops GTZ peptides, a modified A1M-derived peptides which is in preclinical studies for the treatment of CKD and diabet... [Read more]
Financial Performance
Financial StatementsNews
Guard Therapeutics International AB Quarterly report: Q1 2026
Guard Therapeutics International AB has published its Q1 2026 quarterly earnings report on May 11, 2026.
Guard Therapeutics International AB Quarterly report: Q4 2025
Guard Therapeutics International AB has published its Q4 2025 quarterly earnings report on February 20, 2026.
Guard Therapeutics International AB Annual report: Q4 2025
Guard Therapeutics International AB has published its Q4 2025 annual report on February 20, 2026.
Guard Therapeutics International AB Quarterly report: Q3 2025
Guard Therapeutics International AB has published its Q3 2025 quarterly earnings report on November 13, 2025.
Guard Therapeutics International AB Transcript: Study Result
The POINTER phase 2B study of RMC-035 in heart surgery patients did not meet its primary or secondary endpoints, showing no significant benefit over placebo and contrasting with prior AKITA results. Strategic review and full data analysis are ongoing, with likely discontinuation of RMC-035 in this indication.
Guard Therapeutics International AB Press release: Study Result
Guard Therapeutics International AB issued a press release on October 27, 2025, disclosing material business information to investors.
Guard Therapeutics International AB Transcript: DNB Carnegie Småbolagsdag
A late-stage kidney disease program is nearing key phase 2B data, with strong prior results and FDA fast track status. The company is preparing for phase 3, exploring partnerships, and expects significant commercial and regulatory milestones in the coming months.
Guard Therapeutics International AB Quarterly report: Q2 2025
Guard Therapeutics International AB has published its Q2 2025 quarterly earnings report on August 21, 2025.